核苷酸结合寡聚化结构域样受体蛋白3炎症小体及相关通路在精神分裂症中的作用及作为治疗靶点的潜力

Nucleotide-binding oligomerization domain-like receptor protein 3 inflammasomes and associated pathways in schizophrenia:potential as therapeutic targets

近期研究揭示了核苷酸结合寡聚化结构域样受体蛋白3(nucleotide-binding oligomerization domain-like receptor protein 3,NLRP3)炎症小体及其相关通路与精神分裂症神经炎症之间的紧密联系。NLRP3炎症小体的激活及相关通路的异常在一定程度上可能与精神分裂症的精神病性症状、神经传递功能障碍、前脉冲抑制受损以及行为缺陷有关。多种抗精神病药能够通过抑制NLRP3炎症小体或阻断其相关通路来改善精神分裂症的神经炎症。本文对精神分裂症患者及其相关动物模型中与NLRP3炎症小体及其通路相关的研究结果进行总结和讨论,旨在探讨通过调控NLRP3炎症小体及其相关信号通路来治疗精神分裂症的可能性和效果。

Recent studies have revealed a strong association between the nucleotide-binding oligomerization domain-like receptor protein 3(NLRP3)inflammasome and its associated pathways and neuroinflammation in schizophrenia.The activation of the NLRP3-inflammasome and aberrations in its associated pathways may be related to a certain extent to the psychotic symptoms of schizophrenia,neurotransmission dysfunction,impaired prepulse inhibition,and behavioural deficits observed in schizophrenic patients.A variety of antipsychotics can ameliorate neuroinflammation in schizophrenia by inhibiting NLRP3 inflammatory vesicles or blocking their associated pathways.This article summarizes and discusses the research findings related to NLRP3 inflammatory vesicles and their pathways in schizophrenic patients and their relevant animal models.It aims to explore the possibility and efficacy of treating schizophrenia by regulating the NLRP3 inflammatory vesicles and associated signaling pathways.